Enzychem Lifesciences Corporation (183490.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
990.00 KRW
Market cap
83.79 bn KRW
P/E (2025)
–
P/S (2025)
1.24
Dividend yield
0.00 %
Net margin
-26.76 %
Return on equity (ROE)
-13.18 %
Return on assets (ROA)
-12.20 %

Enzychem Lifesciences Corporation financials

Fiscal year20242025
Revenue77.38 bn KRW67.75 bn KRW
Gross profit4.31 bn KRW3.38 bn KRW
Operating income-19.94 bn KRW-13.09 bn KRW
EBIT-21.85 bn KRW-18.04 bn KRW
Net income-22.11 bn KRW-18.13 bn KRW
Diluted EPS – continuing operations-277.65 KRW-242.18 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Enzychem Lifesciences Corporation

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.03.2026. Details in the risk notice.